In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential ... quarter ended December 31, 2024. Evercore ISI analyst Vijay Kumar ...

Evercore ISI has upgraded CRISPR (CRSP) to outperform from in line, citing upcoming data catalysts. Read more here.

In a report released yesterday, Durgesh Chopra from Evercore ISI maintained a Buy rating on Nisource (NI – Research Report), with a price ...

Evercore ISI analysts upgraded CRISPR Therapeutics stock from an In Line to an Outperform rating and increased the price target significantly to $99 from the previous $60. The upgrade comes as ...

Evercore ISI analyst James Kammert maintained a Buy rating on Ventas (VTR – Research Report) yesterday and set a price target of $72.00. The ...

Evercore Inc. has reported its fourth quarter and full-year 2024 results, with net revenues of $975.3 million and $2.98 billion, respectively, on a U.S. GAAP basis. On an adjusted basis, the net ...